Vident Core U.S. Equity Fund (NYSEARCA:VUSE – Get Free Report)’s share price reached a new 52-week high on Tuesday . The stock traded as high as $57.14 and last traded at $57.12, with a volume of 7608 shares. The stock had previously closed at $56.93.
Vident Core U.S. Equity Fund Stock Up 0.3 %
The stock’s fifty day moving average is $54.79 and its 200-day moving average is $53.90. The stock has a market cap of $605.47 million, a price-to-earnings ratio of 17.39 and a beta of 0.94.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VUSE. Vident Advisory LLC boosted its holdings in shares of Vident Core U.S. Equity Fund by 20.8% in the first quarter. Vident Advisory LLC now owns 781,234 shares of the company’s stock valued at $42,504,000 after buying an additional 134,439 shares during the period. Ballentine Partners LLC acquired a new position in Vident Core U.S. Equity Fund in the 2nd quarter worth $2,050,000. Mercer Global Advisors Inc. ADV increased its holdings in Vident Core U.S. Equity Fund by 100.0% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 10,648 shares of the company’s stock worth $574,000 after purchasing an additional 5,324 shares in the last quarter. Willner & Heller LLC acquired a new stake in shares of Vident Core U.S. Equity Fund in the 2nd quarter valued at about $215,000. Finally, Oak Harvest Investment Services bought a new stake in shares of Vident Core U.S. Equity Fund in the second quarter valued at about $201,000.
About Vident Core U.S. Equity Fund
The Vident Core U.S. Equity Fund (VUSE) is an exchange-traded fund that is based on the Vident Core U.S. Stock index. The fund tracks an index of US companies selected and weighted based on a multi-factor model that considers corporate governance, quality, and momentum. VUSE was launched on Jan 22, 2014 and is managed by Vident.
Featured Stories
- Five stocks we like better than Vident Core U.S. Equity Fund
- The Most Important Warren Buffett Stock for Investors: His Own
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Health Care Stocks Explained: Why You Might Want to Invest
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Upcoming IPO Stock Lockup Period, Explained
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Vident Core U.S. Equity Fund Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vident Core U.S. Equity Fund and related companies with MarketBeat.com's FREE daily email newsletter.